Published mark

Travere Therapeutics, Inc.

NASDAQ: TVTX. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:9cae48cc-51cd-487b-8940-6df538bc1781
SEC CIK
0001438533
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 11, 2026
Newest evidence
Apr 6, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Eric Dube, Ph.D.President and Chief Executive Officer
Chair
Gary Lyons
Independent
Not published13 directors published
Published claims
312 distinct sources
Evidence records
50 pinned
Source conflicts
0None open

Built from 2 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Christopher Cline seat on Travere Therapeutics, Inc., effective 2026-04-06.

EffectiveEffective Apr 6, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Named Executive OfficerWenbin Jiang, Ph.D.Apr 2026currentSource reportedE4
Chief Financial OfficerChristopher ClineNot capturedunknownSource reportedE2
Chief Legal Officer, General Counsel and Corporate SecretaryElizabeth E. ReedNot capturedunknownSource reportedE2
President and Chief Executive OfficerEric Dube, Ph.D.Not capturedunknownSource reportedE2
Chief Medical OfficerJula Inrig, M.D.Not capturedunknownSource reportedE2
Chief Commercial OfficerPeter HeermaNot capturedunknownSource reportedE2
Chief Research OfficerWilliam E. Rote, Ph.D.Not capturedunknownSource reportedE2

Board of directors

Evidence

13 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Christopher ClineIndependence not published2026Accrued Compensation (2) CommitteeSource reportedE3
Eric Dube, Ph.D.Independence not published2019Accrued Compensation (2) CommitteeSource reportedE3
Jeffrey MecklerIndependence not published2014None publishedSource reportedE3
John A. OrwinIndependence not published2017None publishedSource reportedE3
Jula Inrig, M.D.Independence not published2026Accrued Compensation (2) CommitteeSource reportedE3
Peter HeermaIndependence not published2026Accrued Compensation (2) CommitteeSource reportedE3
Ron SquarerIndependence not published2017None publishedSource reportedE3
Roy BaynesIndependence not published2016None publishedSource reportedE3
Ruth Williams-BrinkleyIndependence not published2021None publishedSource reportedE3
Sandra PooleIndependence not published2019None publishedSource reportedE3
Suzanne BruhnIndependence not published2020None publishedSource reportedE3
Timothy CoughlinIndependence not published2015None publishedSource reportedE3
William E. RoteIndependence not published2026Accrued Compensation (2) CommitteeSource reportedE3
Gary LyonsIndependentChairNot publishedNone publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
Accrued Compensation (2) CommitteeNot publishedChristopher Cline, Eric Dube, Ph.D., Jula Inrig, M.D., Peter Heerma, William E. RoteNot described in the published record
Committee RecordAccrued Compensation (2) Committee: Chair not stated; Members Christopher Cline; Eric Dube, Ph.D.; Jula Inrig, M.D.; Peter Heerma; William E. Rote
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_record:26
Committee AppointmentChristopher Cline: member, Accrued Compensation (2) Committee
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_appointment:27
Committee AppointmentEric Dube, Ph.D.: member, Accrued Compensation (2) Committee
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_appointment:28
Committee AppointmentJula Inrig, M.D.: member, Accrued Compensation (2) Committee
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_appointment:29
Committee AppointmentPeter Heerma: member, Accrued Compensation (2) Committee
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_appointment:30
Committee AppointmentWilliam E. Rote: member, Accrued Compensation (2) Committee
Source reportedE5
company:9cae48cc-51cd-487b-8940-6df538bc1781:committee_appointment:31

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerEric Dube, Ph.D., President and Chief Executive Officer
Source reportedE2
company:9cae48cc-51cd-487b-8940-6df538bc1781:leadership_role:21
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingTVTX (NASDAQ)
Source reportedE1
company:9cae48cc-51cd-487b-8940-6df538bc1781:security_listing:32
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 11, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameTravere Therapeutics, Inc.
Source reportedE1
company:9cae48cc-51cd-487b-8940-6df538bc1781:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:9cae48cc-51cd-487b-8940-6df538bc1781:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
5 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 11, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC DEF 14A 0001438533-26-000027
    sec def 14a. Published Apr 6, 2026. Retrieved Sep 14, 2026. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    DEF 14A tvtx-20260404.htm
    sec proxy. Published Apr 6, 2026. Retrieved Sep 2, 2026. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    TVTX DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    Accrued Compensation (2) Committee
    governance_people_committees. sec proxy. Cited by 6 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 11, 2026
  • Christopher Cline seat on Travere Therapeutics, Inc., effective 2026-04-06.
  • Jula Inrig, M.D. seat on Travere Therapeutics, Inc., effective 2026-04-06.
  • Peter Heerma seat on Travere Therapeutics, Inc., effective 2026-04-06.
  • William E. Rote seat on Travere Therapeutics, Inc., effective 2026-04-06.
  • Wenbin Jiang, Ph.D. executive of Travere Therapeutics, Inc., effective 2026-04-06.
  • Ruth Williams-Brinkley seat on Travere Therapeutics, Inc., effective 2021-01-01.
  • Suzanne Bruhn seat on Travere Therapeutics, Inc., effective 2020-01-01.
  • Eric Dube, Ph.D. seat on Travere Therapeutics, Inc., effective 2019-01-01.
  • Sandra Poole seat on Travere Therapeutics, Inc., effective 2019-01-01.
  • John A. Orwin seat on Travere Therapeutics, Inc., effective 2017-01-01.
  • Ron Squarer seat on Travere Therapeutics, Inc., effective 2017-01-01.
  • Roy Baynes seat on Travere Therapeutics, Inc., effective 2016-01-01.
  • Timothy Coughlin seat on Travere Therapeutics, Inc., effective 2015-01-01.
  • Jeffrey Meckler seat on Travere Therapeutics, Inc., effective 2014-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:9cae48cc-51cd-487b-8940-6df538bc1781, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/travere-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board14
  5. Committees1
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people17
  17. Subject and corrections6
  18. Evidence5
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:9cae48cc-51cd-487b-8940-6df538bc1781
  • Cite this recordTravere Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/travere-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Travere Therapeutics, Inc.Company
  • Wenbin Jiang, Ph.D.Person
  • Christopher ClinePerson
  • Elizabeth E. ReedPerson
  • Eric Dube, Ph.D.Person
  • Jula Inrig, M.D.Person
  • Peter HeermaPerson
  • William E. Rote, Ph.D.Person
  • Jeffrey MecklerPerson
  • John A. OrwinPerson
  • Ron SquarerPerson
  • Roy BaynesPerson
  • Ruth Williams-BrinkleyPerson
  • Sandra PoolePerson
  • Suzanne BruhnPerson
  • Timothy CoughlinPerson
  • William E. RotePerson
  • Gary LyonsPerson
  • Sections
    OverviewTravere Therapeutics, Inc.
  • MonitoringTravere Therapeutics, Inc.
  • LeadershipTravere Therapeutics, Inc.
  • BoardTravere Therapeutics, Inc.
  • CommitteesTravere Therapeutics, Inc.
  • Control and votingTravere Therapeutics, Inc.
  • Authority to actTravere Therapeutics, Inc.
  • FinancialsTravere Therapeutics, Inc.
  • GovernanceTravere Therapeutics, Inc.
  • RiskTravere Therapeutics, Inc.
  • AI oversightTravere Therapeutics, Inc.
  • LegalTravere Therapeutics, Inc.
  • CompensationTravere Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.